New hope for tough cancers: first patients test experimental drug

NCT ID NCT07030959

Recruiting now Disease control Sponsor: Chugai Pharmaceutical Source: ClinicalTrials.gov ↗

Summary

This is the first study in people to test a new drug called AUBE00 for patients with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and check for any early signs that it might help shrink tumors. It will enroll up to 130 adults whose cancers have a specific genetic change called KRAS.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cancer Center Hospital
RECRUITING

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East
RECRUITING

Kashiwa, Chiba, 277-8577, Japan
South Texas Accelerated Research Therapeutics (START) Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

Conditions

Explore the condition pages connected to this study.

SOLID TUMORS